Currently in Phase 3 trials for estrogen receptor-positive, HER2-negative breast cancer, ARV-471 has demonstrated a superior ability to degrade estrogen receptor compared to conventional selective estrogen receptor degraders, such as fulvestrant, potentially improving treatment outcomes in hormone therapy-resistant patients [14]. This evidence concerns the gene ESR1 and breast carcinoma.